Exhale

The official blog of the Lung Institute.

What Is the Life Expectancy of a Person With Pulmonary Fibrosis?

What Is the Life Expectancy of a Person With Pulmonary Fibrosis?

Pulmonary fibrosis is a condition that usually becomes more severe over time. As lung scarring and inflammation become more pronounced, they can significantly impact a person’s life expectancy and quality of life.

The extent of this impact, however, can vary from person to person. Some people with pulmonary fibrosis live for many years after their diagnosis and are able to participate in most, if not all, of their normal daily activities. Other people have more severe complications that interfere with their day-to-day function and affect their overall outcome.

Factors that can influence a person’s prognosis include his or her:

  • Age
  • Medical history
  • Personal response to treatment

A person’s lifestyle can also impact his or her prognosis. For instance, people who do not smoke often have a better life expectancy than those who use tobacco products. People who exercise regularly also tend to have a higher quality of life.

Currently, there is no cure for pulmonary fibrosis. However, it may be possible to slow the progression of the disease. Cellular therapy, for instance, is an alternative treatment option that has the potential to alleviate inflammation.

At the Lung Institute, we offer two types of cellular therapy for pulmonary fibrosis. Both of these treatments use a patient’s own cells to promote the body’s natural healing process. These therapies are offered on an outpatient basis and are not associated with any major side effects. More than 80 percent of our patients report an improved quality of life after receiving cellular therapy at the Lung Institute.

If you or a loved one has been diagnosed with pulmonary fibrosis and would like to learn more about cellular therapy, contact us at 888-745-6697. Our caring and experienced team is here for you whenever you are ready.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.